Advertisement





Click here for more guidelines.
CME Topic Collections Past Issues Search Current Issue Home
     

J Am Coll Cardiol, 2008; 51:1539-1542, doi:10.1016/j.jacc.2007.12.041
© 2008 by the American College of Cardiology Foundation
This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (3)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ambrose, J. A.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Ambrose, J. A.

VIEWPOINT

In Search of the "Vulnerable Plaque"

Can it Be Localized and Will Focal Regional Therapy Ever Be an Option for Cardiac Prevention?

John A. Ambrose, MD, FACC*

University of California, San Francisco, Fresno, California.

Manuscript received September 25, 2007; revised manuscript received December 7, 2007, accepted December 17, 2007.

* Reprint requests and correspondence: Dr. John A. Ambrose, 2823 Fresno Street, Fresno, California 93721. (Email: jamambrose{at}yahoo.com).

The search to find the location of future plaque ruptures or plaque erosions leading to myocardial infarction (so-called "vulnerable plaques") is an important area of cardiovascular research. Systemic therapy, including use of statins, targets the vulnerable patient. However, adverse events cannot be completely eliminated with the appropriate application of systemic therapies and thus has given rise to the possibility of local or regional therapy of "vulnerable plaques" to prevent future events. Until now, no criteria have been developed for consideration of this therapy. For such a strategy to work, there should be several prerequisites. These involve the identification of susceptible lesions, the number of lesions, their natural history, and proof that an interventional technique is preferable to medical therapy alone. The greatest deficiency relates to the fact that until the natural history of presumed "vulnerable plaques" is known one can never truly identify what constitutes a "vulnerable plaque." Much work needs to be done in this area, but ongoing and new trials should provide important information that could potentially change drastically how coronary artery disease is diagnosed and treated.

Abbreviations and Acronyms
  IVUS = intravascular ultrasound
  OCT = optical coherence tomography
  TCFA = thin-capped fibroatheroma




This article has been cited by other articles:


Home page
J Am Coll Cardiol IntvHome page
R. Chacko, M. Mulhearn, V. Novack, L. Novack, L. Mauri, S. A. Cohen, J. Moses, M. B. Leon, and D. E. Cutlip
Impact of Target Lesion and Nontarget Lesion Cardiac Events on 5-Year Clinical Outcomes After Sirolimus-Eluting or Bare-Metal Stenting
J. Am. Coll. Cardiol. Intv., June 1, 2009; 2(6): 498 - 503.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Roentgenol.Home page
A. J. Duerinckx
The Nonculprit Coronary Lesion as Seen by Coronary CT Angiography: What Should We Be Looking For?
Am. J. Roentgenol., August 1, 2008; 191(2): 439 - 440.
[Full Text] [PDF]



 
  CME Topic Collections Past Issues Search Current Issue Home

Advertisement